Leerink Partners thesis on Surgery Partners (SGRY) 'unchanged' as Bain deal collapses
Tweet Send to a Friend
Leerink Partners analyst Whit Mayo reiterated an Outperform rating and $34.00 price target on Surgery Partners (NASDAQ: SGRY), with shares ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


